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ORIGINAL ARTICLE
Tuberculosis (TB) has been a leading health prob-
lem for many years and remains a major cause of
death worldwide. In 2005, there were an estimated
8.8 million new TB cases, and 1.6 million people
died of TB.1 Although short-course chemotherapy
has been highly effective,2 side effects, especially
hepatotoxicity, complicate treatment and cause
significant morbidity and mortality.3 The reported
incidence of hepatitis during antituberculous treat-
ment varies from 2.4% to 26%,3–25 and guidelines
from Europe and America give different recom-
mendations on monitoring and managing prob-
able hepatotoxicity in TB patients undergoing
treatment.2,26 Given the possible occurrence of
hepatitis, clinicians are apt to discontinue isoni-
azid (INH), rifampin (RIF) or pyrazinamide (PZA)
once liver function tests are elevated above normal
ranges, which makes adequate treatment duration
uncertain for patients treated with nonstandard
regimens. In addition, it has been reported that
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Asian populations have a higher risk of hepatotox-
icity than their Western counterparts, and ethnic-
ity and genetics are considered to play a role.12
Therefore, the present study prospectively assessed
the incidence and risk factors for development of
hepatitis in Taiwanese patients with various un-
derlying diseases. Additionally, previous studies
that have reported the incidence of hepatitis dur-
ing antituberculous treatment were reviewed for
comparison with our study results.
Methods
We prospectively enrolled patients diagnosed
with TB and receiving antituberculous agents at
the divisions of chest and infectious diseases at
National Taiwan University Hospital from July 1,
2000 to July 31, 2001. Patients were followed until
November 30, 2001. A standardized case record
form was used to record patient demographics (age,
sex, height, weight, daily drinking habits, initial
albumin level, pulmonary or extrapulmonary TB,
underlying diseases, and concurrent use of other
hepatotoxic drugs); antituberculous agents (regi-
men and dosage); serology testing for hepatitis 
B virus (HBV), hepatitis C virus (HCV) and human
immunodeficiency virus (HIV) infection before
treatment; baseline and monthly biochemistry tests
after treatment (including aspartate aminotrans-
ferase [AST], alanine aminotransferase [ALT], alka-
line phosphatase [ALP], γ-glutamyl transpeptidase
[γGT], and total and direct bilirubin); associated
symptoms/signs of hepatitis (including poor ap-
petite, nausea, vomiting, fatigue, lower leg edema,
abdominal discomfort, and jaundice); and man-
agement of hepatitis (including observation, change,
or discontinuation of antituberculous agents).
Hepatitis was defined as an elevated ami-
notransferase level > 5 times the upper limit of
normal (ULN) (men, ALT < 41 U/L, AST < 37 U/L;
women, ALT < 31 U/L, AST < 31 U/L) (with or with-
out symptoms), or > 3 times ULN in the presence
of symptoms, or elevated total bilirubin > 3 mg/dL
(normal range, 0.2–1.2 mg/dL).2 The severity of
hepatitis was considered mild if AST or ALT level
was < 5 times ULN, moderate if AST or ALT level
was 5–10 times ULN, and severe if AST or ALT
level was > 10 times ULN.27 The Institutional
Review Board of the hospitals approved the study.
English-language reports of published studies
reporting the incidence of hepatitis in TB patients
during antituberculous treatment were identified
from PubMed (http://www.ncbi.nlm.nih.gov)
(1966 to November 2007) by cross-referencing the
key words “incidence”, “hepatitis”, and “antitu-
berculous” for comparison with our results. Bib-
liographies of original articles were reviewed for
additional studies. The definitions of hepatitis var-
ied substantially among studies ranging from mild
elevation of ALT (1.5 times higher than ULN)14,15
to significant elevation of AST/ALT (5 times 
higher than ULN)3,8,11,12,16,18,19 or symptomatic
hepatitis.3,7 With regard to the exclusion criteria,
some studies excluded all other causes of hepatitis,
such as concurrent use of other hepatotoxic drugs,
or viral, alcoholic or other systemic diseases, and
focused on only antituberculous-drug-induced
hepatitis,3–5,11,12,21,23 while some tried to evaluate
the incidence of hepatitis during antituberculous
treatment in patients with HBV,6,10,14,20 HCV,9,15,20
or HIV infection.15,18,20,24 In addition, some stud-
ies enrolled patients with multiple underlying
diseases.7,13,15–17,19,20,22,24,25
Statistical analysis
Statistical analysis was performed with SPSS version
15.0 (SPSS Inc., Chicago, IL, USA). Categorical vari-
ables were compared by χ2 test or Fisher’s exact test.
Non-categorical variables were compared by the
Mann–Whitney U test. Odds ratio (OR), 95% con-
fidence interval (CI), and multiple logistic regres-
sion were used to assess the risk factors associated
with development of hepatitis during treatment.
A value of p < 0.05 was considered significant.
Results
We enrolled 261 patients treated with antituber-
culous agents. Their demographics are presented
in Table 1. The median age was 58 years (range,
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Table 1. Patient demographics during antituberculous treatment*
Total patients
Patients with Patients without 
p
hepatitis hepatitis
Patients 261 (100%) 42 (16.1%) 219 (83.9%)
Men 164 (62.8%) 27 (64.3%) 137 (62.6%) 0.832
Age (yr) 58 (17–90) 60 (19–89) 58 (17–90) 0.904
> 35 212 (81.2%) 36 (85.7%) 176 (80.4%) 0.416
> 65 94 (36.0%) 14 (33.3%) 80 (36.5%) 0.693
Body mass index (kg/m2) 20.7 (11.6–30.3) 20.8 (13.5–29.3) 20.7 (11.6–30.3) 0.899
Initial albumin level (mg/dL) 3.7 (1.9–5.2) [207]† 3.4 (1.9–4.7) [39]† 3.7 (1.9–5.2) [168]† 0.040
Initial albumin < 3.5 mg/dL 92 (44.4%) [207]† 25 (64.1%) [39]† 67 (39.9%) [168]† 0.006
Abnormal baseline tests 31 (17.7%) [175]† 13 (44.8%) [29]† 18 (12.3%) [146]† < 0.001
AST level (U/L) 22 (7–308) [158]† 28 (9–94) [23]† 21 (7–308) [134]† 0.028
> 2 × ULN 4 (2.5%) [157]† 2 (8.7%) [23]† 2 (1.5%) [134]† 0.103
ALT level (U/L) 17 (4–252) [155]† 23 (8–149) [27]† 16 (4–252) [128]† 0.011
> 2 × ULN 8 (5.2%) [155]† 4 (14.8%) [27]† 4 (3.1%) [128]† 0.044
Total bilirubin (mg/dL) 0.5 (0.1–3.3) [135]† 0.7 (.3–3.3) [23]† 0.5 (0.1–2.8) [112]† 0.003
> 2 mg/dL 3 (2.2%) [135]† 2 (8.7%) [23]† 1 (0.9%) [112]† 0.075
Concurrent hepatotoxic drug use 48 (18.4%) 7 (16.7%) 41 (18.7%) 0.753
Pulmonary TB 227 (87.0%) 33 (78.6%) 194 (88.6%) 0.077
Underlying diseases
Alcohol use 32 (12.3%) 6 (14.3%) 26 (11.9%) 0.662
Diabetes mellitus 66 (25.3%) 10 (23.8%) 56 (25.6%) 0.810
Hypertension 65 (24.9%) 14 (33.3%) 51 (23.3%) 0.168
HBV infection 15 (5.7%) 6 (14.3%) 9 (4.1%) 0.026
HCV infection 17 (6.5%) 5 (11.9%) 12 (5.5%) 0.228
Liver cirrhosis 14 (5.4%) 6 (14.3%) 8 (3.7%) 0.015
HIV infection 15 (5.7%) 5 (11.9%) 10 (4.6%) 0.131
CD4 (cells/μL) 37 (11–319) [15]† 118 (12–319) [5]† 33 (11–134) [10]† 0.269
PVL (log10 copies/mL) 5.2 (2.6–5.9) [15]† 5.2 (2.6–5.9) [5]† 5.4 (2.7–5.9) [10]† 0.618
HAART use 14 (93.3%) [15]† 4 (80.0%) [5]† 10 (100%) [10]† 0.333
Malignancy 25 (9.6%) 5 (11.9%) 20 (9.1%) 0.785
Other diseases 88 (33.7%) 16 (38.1%) 72 (32.9%) 0.512
Initial regimen
HERZ or HRZ 217 (83.1%) [261]† 35 (83.3%) [42]† 182 (83.1%) [219]† 0.971
INH dose (mg/kg/d) 5.6 (2.4–8.8) [260]† 5.6 (3.8–8.2) [42]† 5.6 (2.4–8.8) [218]† 0.527
RIF dose (mg/kg/d) 10.1 (4.2–16.7) [254]† 10.2 (6.2–16.3) [38]† 10 (4.2–16.7) [216]† 0.758
> 10 mg/kg/d 127 (50.0%) [254]† 20 (52.6%) [38]† 107 (49.5%) [216]† 0.725
EMB dose (mg/kg/d) 15.7 (5.5–30.2) [250]† 15.7 (5.5–30.2) [40]† 15.8 (7.1–30) [210]† 0.978
PZA dose (mg/kg/d) 25.4 (9.6–41.7) [219]† 25 (11.7–35.1) [35]† 25.4 (9.6–41.7) [184]† 0.157
Regimen adjustment 81 (31.0%) 34 (81.0%) 47 (21.5%) < 0.001
Mortality 6 (2.3%) 2 (4.8%) 4 (1.8%) 0.248
*Data presented as n (%) or median (range); †number of patients with data available in the square brackets. AST = aspartate aminotransferase; ALT = alanine
aminotransferase; ULN = upper limit of normal; TB = tuberculosis; HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus;
PVL = plasma viral load; HAART = highly active antiretroviral therapy; INH (H) = isoniazid; RIF (R) = rifampin; EMB (E) = ethambutol; PZA (Z) = pyrazinamide.
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17–90 years), and 164 were men (62.8%). Diabetes
mellitus was the most common underlying disease
(66 patients, 25.3%), followed by hypertension
(65, 24.9%). Fifteen patients (5.7%) had HBV in-
fection, 17 (6.5%) had HCV infection, 15 (5.7%)
had HIV infection, and 14 (5.4%) had liver cirrho-
sis. Other diseases included malignancy, benign
prostatic hypertrophy, gout, chronic obstructive
pulmonary disease, asthma, cerebrovascular acci-
dent, coronary artery disease, and arrhythmia.
Forty-eight patients (18.4%) used other hepa-
totoxic drugs concurrently during antituberculous
treatment. The commonly used drugs included
acetaminophen (12, 25.5%), indinavir (9, 19.1%),
sulfonylurea (7, 14.9%), prednisolone (7, 14.9%),
and diclofenac (4, 8.5%). HERZ (H, isoniazid; 
E, ethambutol; R, rifampin; Z, pyrazinamide) was
the most common antituberculous regimen (210
patients, 80.5%) followed by HER (36, 13.8%),
HRZ (7, 2.7%) and others (8, 3.1%). Sequential
monthly changes in median AST, ALT, and total
bilirubin level are shown in the Figure. The great-
est changes in median AST and ALT level were
observed in the second month of antituber-
culous treatment, while no significant change in
median total bilirubin level was noted during
treatment.
Forty-two patients (16.1%) met our definition
of hepatitis during antituberculous treatment,
and the median peak AST was 228.5 U/L (range,
104–2854 U/L) after a median treatment dura-
tion of 45 days (range, 11–171 days); peak ALT
was 243 U/L (range, 100–968 U/L) after a median
treatment duration of 46 days (range, 11–162
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Figure. Box plots of sequential monthly changes in: (A) aspartate aminotransferase (AST) level; (B) alanine aminotransferase
(ALT) level; and (C) total bilirubin (T-bil) level in all patients with tuberculosis receiving antituberculous agents (box plot from
bottom to top: smallest non-outlier observation; first quartile; median; third quartile; largest non-outlier observation).
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Table 2. Hepatitis symptoms and peak levels of liver function tests*
Total patients
Patients with Patients without 
p
hepatitis hepatitis
Patients 261 (100%) 42 (16.1%) 219 (83.9%)
Symptoms of hepatitis 64 (24.5%) 18 (42.9%) 46 (21.0%) 0.003
Anorexia 20 (7.7%) 6 (14.3%) 14 (6.4%) 0.055
Nausea/vomiting 34 (13.0%) 8 (19.0%) 26 (11.9%) 0.085
Malaise/fatigue 13 (5.0%) 1 (2.4%) 12 (5.5%) 0.254
Jaundice 8 (3.1%) 7 (16.7%) 1 (0.5%) < 0.001
Peak AST level (U/L) 37.5 (12–2854) [260]† 228.5 (104–2854) [22]† 35 (12–160) [238]† < 0.001
Duration of Tx (d) 48.5 (4–180) 45 (11–171) 48.5 (4–180) 0.372
< 1 mo 87 (33.5%) 4 (18.2%) 83 (34.9%) 0.112
< 2 mo 158 (60.8%) 13 (59.1%) 145 (60.9%) 0.866
< 3 mo 194 (74.6%) 15 (68.2%) 179 (75.2%) 0.469
Peak AST > 1 × ULN 145 (55.8%) 22 (100%) 123 (51.7%) –
Peak AST > 2 × ULN 66 (25.4%) 22 (100%) 44 (18.5%) –
Peak AST > 3 × ULN 23 (12.7%) 22 (100%) 11 (4.6%) –
Peak AST > 5 × ULN 16 (6.2%) 16 (72.7%) 0 (0%) –
Peak ALT level (U/L) 35 (5–968) [259]† 243 (100–968) [30]† 31 (5–205) [229]† < 0.001
Duration of Tx (d) 48 (5–179) 46 (11–162) 48 (5–179) 0.735
< 1 mo 82 (31.7%) 6 (20.0%) 76 (33.2%) 0.144
< 2 mo 156 (60.2%) 19 (63.3%) 137 (59.8%) 0.712
< 3 mo 198 (76.4%) 23 (76.7%) 175 (76.4%) 0.976
Peak ALT > 1 × ULN 126 (48.6%) 30 (100%) 96 (41.9%) –
Peak ALT > 2 × ULN 64 (24.7%) 30 (100%) 34 (14.8%) –
Peak ALT > 3 × ULN 44 (17.0%) 30 (100%) 14 (6.1%) –
Peak ALT > 5 × ULN 26 (10.0%) 26 (86.7%) 0 (0%) –
Peak total bilirubin (mg/dL) 0.7 (0.2–19.6) [221]† 5 (3.2–19.6) [15]† 0.6 (0.2–2.9) [206]† < 0.001
Duration of Tx (d) 43 (4–180) 42 (4–156) 45.5 (4–180) 0.789
< 1 mo 86 (38.9%) 6 (40.0%) 80 (38.8%) 0.929
< 2 mo 132 (59.7%) 9 (60.0%) 123 (59.7%) 0.982
< 3 mo 161 (72.9%) 10 (66.7%) 151 (73.3%) 0.797
Peak total bilirubin > 1.2 mg/dL 47 (21.3%) 15 (100%) 32 (15.5%) –
Peak total bilirubin > 2 mg/dL 23 (10.4%) 15 (100%) 8 (3.9%) –
Peak total bilirubin > 3 mg/dL 15 (6.8%) 15 (100%) 0 (0%) –
*Data presented as n (%) or median (range); †number of patients with data available in the square brackets. Tx = treatment; AST = aspartate aminotrans-
ferase; ALT = alanine aminotransferase; ULN = upper limit of normal.
days); and peak total bilirubin level was 5 mg/dL
(range, 3.2–19.6 mg/dL) after a median treatment
duration of 42 days (range, 4–156 days). Approxi-
mately 60% of the events occurred in the first 2
months of treatment (Table 2). The severity of
hepatitis was mild in 13 (31.0%) of these 42 pa-
tients, moderate in 18 (42.9%), and severe in 11
(26.2%). More patients with hepatitis had asso-
ciated symptoms than those without (42.9 vs.
21.0%, p = 0.003), especially jaundice (16.7 vs.
0.5%, p < 0.001) (Table 2). Of the 219 patients
without hepatitis, 51.7%, 41.9%, and 15.5% had
elevated AST, ALT and total bilirubin level higher
than ULN during treatment. Furthermore, 18.5%
and 14.8% had elevated AST and ALT levels 
2 times higher than ULN. Similar to patients with
hepatitis, 60% of the peak elevation occurred in
the first 2 months of treatment.
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Compared with patients without hepatitis, a
significantly higher proportion of patients with
hepatitis had an initial albumin level < 3.5 mg/dL,
abnormal liver function tests at baseline, HBV in-
fection, and liver cirrhosis (Table 1). By multiple
logistic regression with adjustment for initial al-
bumin level < 3.5 mg/dL and HBV infection, only
abnormal liver function tests at baseline (OR,
2.966; 95% CI, 1.059–8.310) and liver cirrhosis
(OR, 6.044; 95% CI, 1.143–31.951) were inde-
pendent risk factors associated with the develop-
ment of hepatitis (Table 3). Up to 81.0% of the
patients with hepatitis and 21.5% without hepa-
titis had regimen adjustment, including discon-
tinuation of antituberculous agents or change of
regimen. Most physicians discontinued agents
when the AST or ALT level was 2–3 times higher
than ULN. Six patients (2.3%) died at the end of
the study, but no deaths were attributed to hepatic
failure.
Discussion
The present study found a 16.1% incidence of hep-
atitis in Taiwanese patients with various under-
lying diseases receiving antituberculous treatment.
Abnormal liver function tests at baseline and liver
cirrhosis were independent risk factors for devel-
opment of hepatitis. Reviewing the literature, the
incidence of hepatitis was 2.4–19% in Western
countries16–25 and 5.3–18.2% in other Asian coun-
tries (Table 4).8–15 Although ethnicity and genetics
might play a role,12 these differences are mainly
attributable to different inclusion and exclusion
criteria and variable definitions of hepatitis. After
exclusion of other possible causes for hepatitis, the
incidence that focused on antituberculous-drug-
induced hepatitis was 8–17%,3–5,11,12,21,23 while
the incidence of hepatitis during antituberculous
therapy was 9.8–34.9% in HBV patients,6,10,14,20
13–30% in HCV patients,9,15,20 and 13–27.3% in
HIV patients.15,18,20,24 Some previous studies en-
rolled patients with multiple underlying diseases
and, similar to our study, the incidence of hepati-
tis ranged from 2.4% to 19%.7,13,15–17,19,20,22,24,25
Previous reports from Taiwan have shown a
wide range of incidence of hepatitis (2.4–26%)
during antituberculous treatment (Table 3).4–7
The study by Wu et al showed an incidence of
symptomatic hepatitis of 2.4%, without specific
definition of abnormal liver function tests,7 and
the remaining three studies gave an incidence of
antituberculous-drug-induced hepatitis of 14.7%
and 15.4% by Huang et al4,5 and up to 26% by
Hwang et al.6 Although other causes for hepatitis
were excluded, the incidence was still high in the
study by Hwang et al.6 This high incidence might
be explained by the lack of specific laboratory cri-
teria for hepatitis, and up to 68% of patients had
AST levels 1–2 times higher than ULN. In addition,
the status of liver cirrhosis in HBV carrier patients
was unknown.6 In the present study, we did not
exclude patients with abnormal liver function tests
at baseline, in an attempt to mimic daily practice.
If incidence of hepatitis in patients with and with-
out abnormal baseline liver function tests was
analyzed separately, the incidence was up to 41.9%
in those with abnormal baseline tests and 11.1%
with normal baseline data (p < 0.001).
Reported risk factors for hepatitis during 
antituberculous treatment include advanced
Table 3. Variables associated with development of hepatitis during antituberculous therapy by multiple
logistic regression
Risk factors OR 95% CI p
Abnormal baseline tests 2.966 1.059–8.310 0.039
Initial albumin < 3.5 mg/dL 2.580 0.957–6.955 0.061
HBV infection 2.298 0.397–13.298 0.353
Liver cirrhosis 6.044 1.143–31.951 0.034
OR = odds ratio; CI = confidence interval; HBV = hepatitis B virus.
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age,5,6,12–14,19,21,22 female gender,22 high alcohol
intake,28 abnormal pretreatment liver tests,13 ex-
isting HBV,7,14 HCV20 or HIV infection,20,24 hy-
poalbuminemia,12 acetylator status,5 HLA-DQB1*
0201,12 and CYP2E1 genotype.4 Therefore, guide-
lines from the American Thoracic Society recom-
mend routine measurement of liver function tests
for patients with baseline abnormalities, who
chronically consume alcohol, take other poten-
tially hepatotoxic medications, or have viral hep-
atitis, a history of liver disease, HIV infection, or
a history of prior TB-drug-induced liver injury,
after baseline measurements for all adults begin-
ning treatment for TB.29
In our study, abnormal liver function tests 
at baseline and liver cirrhosis were identified as
independent risk factors for development of hep-
atitis during antituberculous treatment. Teleman
et al also showed that patients with abnormal
baseline transaminase are at risk for develop-
ment of hepatitis during treatment,13 and Cho 
et al demonstrated that patients with liver cirrho-
sis have an insignificantly higher incidence of
hepatitis than those without liver disease (27% vs.
10%, p = 0.079).8 Taiwan is an area of high HBV
endemicity, with up to 17.3% of the general 
population being positive for hepatitis B surface
antigen (HBsAg), while positivity for anti-HCV
antibody is 4.4%.30 However, in the present
study, only 48 and 47 patients had HBsAg and
anti-HCV antibody checked, respectively, and
only four patients each were found to have HBV
or HCV infection. The information about HBV 
or HCV infection in the remainder of the pa-
tients was acquired by history taking. Therefore,
the influence of HBV and HCV infection on the
incidence of hepatitis might have been underes-
timated. According to our findings, routine mea-
surement of HBsAg deserves to be considered in
patients beginning antituberculous treatment in
Taiwan because of the high prevalence of HBV
infection.
Prior studies have demonstrated that transient
elevation of AST/ALT (1–3 times higher than ULN)
was observed in 26% of HBV carriers and 28% of
HCV carriers.9,10 Shakya et al reported that 38%
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and 40% of patients undergoing antituberculous
treatment had ALT and AST levels two times higher
than the pretreatment level.11 In our study, we
found that 50% and 40% of the patients without
hepatitis had elevated AST and ALT level higher
than ULN, and 19% and 15% had elevated AST
and ALT levels > 2 times ULN (Table 2). In addi-
tion, 21.0% of our patients without hepatitis had
loss of appetite, fatigue or jaundice, but their liver
function tests did not meet our criteria of hepati-
tis, which means that such symptoms might be
attributable to causes other than hepatitis. Among
patients without hepatitis, only 21.5% had regi-
men adjustment, and none developed hepatic
failure at the end of the study. Therefore, therapy
should not be altered simply because of mild 
elevation of liver function tests or mild symptoms
without significant changes in liver function tests,
because the efficacy of isoniazid and rifampin
warrants their use and asymptomatic aminotrans-
ferase elevations resolve spontaneously in most
patients.2 Instead, the frequency of clinical and
laboratory monitoring should be increased, per-
haps every 2 weeks or when clinically indicated,
to decide if further regimen adjustment is needed.
Such follow-up might be useful for patients with
abnormal liver function tests at baseline or with
liver cirrhosis. Discontinuation of the important
first-line agents will substantially prolong treat-
ment duration, and the efficacy of adjusted regi-
mens is not guaranteed without potent first-line
agents.2
There were several limitations to our study.
First, it is difficult to determine the true incidence
of antituberculous-drug-induced hepatitis in the
presence of numerous associated factors. However,
we presented an incidence of hepatitis during an-
tituberculous treatment in patients with multiple
underlying diseases that most closely simulates
daily clinical practice. Second, patients with HBV
infection might be underestimated because not
all patients had their HBsAg status checked. Third,
limited resources prevented continuation of this
prospective study and limited the number of cases
studied. With these limitations, we conclude that,
although definitions of hepatitis and populations
are different between studies, the incidence of
hepatitis during antituberculous treatment in
Taiwanese patients with various underlying dis-
eases is similar to that reported in other Asian
countries, and slightly higher than that in Western
countries. Elevation of liver function tests was not
uncommon during antituberculous treatment,
especially in the first 2 months. Judicious follow-
up of clinical condition and liver function tests,
especially in patients with abnormal liver function
tests at baseline or with liver cirrhosis, should be
implemented.
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